-
Associations of urinary fetuin-a with histopathology and kidney events in biopsy-proven kidney disease Clin. Kidney J. (IF 4.6) Pub Date : 2024-03-15 Ming-Tsun Tsai, Wei-Cheng Tseng, Kuo-Hua Lee, Chih-Ching Lin, Shuo-Ming Ou, Szu-yuan Li
Background Fetuin-A is implicated in the pathogenesis of vascular calcification in chronic kidney disease (CKD); however, the relationship between fetuin-A, histopathologic lesions, and long-term kidney outcomes in patients with various types of kidney disease remains unclear. Methods We measured urinary fetuin-A levels in 335 individuals undergoing clinically indicated native kidney biopsy. The expressions
-
Associations of MRI-derived kidney volume, kidney function, body composition, and physical performance in ∼38,000 UK Biobank participants: a population-based observational study Clin. Kidney J. (IF 4.6) Pub Date : 2024-03-15 Jeong Min Cho, Jung Hun Koh, Seong Geun Kim, Soojin Lee, Yaerim Kim, Semin Cho, Kwangsoo Kim, Yong Chul Kim, Seung Seok Han, Hajeong Lee, Jung Pyo Lee, Kwon Wook Joo, Chun Soo Lim, Yon Su Kim, Dong Ki Kim, Sehoon Park
Background Kidney volume is used as predictive and therapeutic marker for several clinical conditions. However, there is a lack of large-scale studies examining the relationship between kidney volume and various clinicodemographic factors, including kidney function, body composition, and physical performance. Methods In this observational study, MRI-derived kidney volume measurements from 38,526 UK
-
[18F] AlF-NOTA-FAPI-04 PET/CT for non-invasive assessment of tubular injury in kidney diseases Clin. Kidney J. (IF 4.6) Pub Date : 2024-03-15 Hao Wang, Ping Zhang, Wei Wang, Limeng He, Nan Liu, Juan Yang, Deying Tang, Guisen Li, Yunlin Feng, Wei Zhang
Background [18F] AlF-NOTA-FAPI-04 is a novel positron emission tomography (PET) ligand, which specifically targets fibroblast activation protein (FAP) expression as a FAP inhibitor (FAPI). We analyzed the diagnostic value of [18F] AlF-NOTA-FAPI-04 PET/CT for the non-invasive assessment of kidney interstitial inflammation and fibrosis in different renal pathologies. Methods Twenty-six patients (14 males
-
Differences in drug removal between standard high-flux and medium cut-off dialyzers in a case of severe vancomycin toxicity Clin. Kidney J. (IF 4.6) Pub Date : 2024-03-14 Simon Aberger, Michael Kolland, Kathrin Eller, Alexander R Rosenkranz, Alexander H Kirsch
Vancomycin is a widely used glycopeptide antibiotic with the need for therapeutic drug monitoring to avoid renal toxicity. We report a case of severe vancomycin-associated anuric acute kidney injury managed with successful drug-removal by hemodialysis (HD) using different types of dialyzers. Medium cut-off (MCO) and high-flux dialyzers were effective in drug removal. Higher vancomycin elimination rate
-
Simulation-based learning in nephrology Clin. Kidney J. (IF 4.6) Pub Date : 2024-03-13 Valentin Maisons, Antoine Lanot, Yosu Luque, Benedicte Sautenet, Emmanuel Esteve, Erwan Guillouet, Hélène François, Mickaël Bobot
Simulation is a technique to replace and amplify real experiences with guided ones, that evoke or replicate substantial aspects of the real world in a fully interactive fashion. In nephrology (a particularly complex specialty), simulation can be used by patients, nurses, residents and attendings alike. It allows you to learn techniques outside of the stressful environment of care such as: central venous
-
Chronic kidney disease duration and suicide risk among maintenance hemodialysis patients in China Clin. Kidney J. (IF 4.6) Pub Date : 2024-03-12 Xinyue Wang, Xinmei Hao, Mi Ma, Wei Jiang, Baoshuang Li, Yan Xu, Ping Sun
To investigate the relationship between chronic kidney disease (CKD) duration and suicide risk among patients with maintenance hemodialysis (MHD). Patients with end-stage renal disease (ESRD) who received MHD were enrolled. The demographic and disease characteristics of MHD patients were collected using a self-designed basic information questionnaire. The Suicide Risk Assessment Scale was used to assess
-
Fine-tuning tumor- and allo-immunity: advances in the use of immune checkpoint inhibitors in kidney transplant recipients Clin. Kidney J. (IF 4.6) Pub Date : 2024-03-09 Tess Van Meerhaeghe, Naoka Murakami, Alain Le Moine, Sophie Brouard, Ben Sprangers, Nicolas Degauque
Cancer is a common complication after kidney transplantation. Kidney transplant recipients (KTR) have a 2-to-4-fold higher risk of developing cancer compared to the general population and post-transplant malignancy is the third most common cause of death in KTR. Moreover, it is well known that certain cancer types are overrepresented after transplantation, especially non-melanoma skin cancer. Immune
-
Kidney involvement in Wilson's disease: a review of the literature Clin. Kidney J. (IF 4.6) Pub Date : 2024-03-09 Julien Dang, Kevin Chevalier, Emmanuel Letavernier, Come Tissandier, Sarah Mouawad, Dominique Debray, Mickaël Obadia, Aurélia Poujois
Wilson's disease (WD) is a rare inherited disease due to the mutation of the ATP7B gene, resulting in impaired hepatic copper excretion and its pathological accumulation in various organs such as the liver, the nervous system, or the kidneys. While liver failure and neuropsychiatric disorders are the most common features, less is known about the renal complications. We conducted a review of the literature
-
Association between diabetic status and risk of all-cause and cause-specific mortality on dialysis following first kidney allograft loss Clin. Kidney J. (IF 4.6) Pub Date : 2024-03-07 Amali Samarasinghe, Germaine Wong, Armando Teixeira-Pinto, David W Johnson, Carmel Hawley, Helen Pilmore, William R Mulley, Matthew A Roberts, Kevan R Polkinghorne, Neil Boudville, Christopher E Davies, Andrea K Viecelli, Esther Ooi, Nicholas G Larkins, Charmaine Lok, Wai H Lim
Background Diabetes mellitus (DM) is associated with a greater risk of mortality in kidney transplants patients, primarily driven by a greater risk of cardiovascular disease (CVD)-related mortality. However, the associations between diabetes status at time of first allograft loss and mortality on dialysis remain unknown. Methods All patients with failed first kidney allografts transplanted in Australia
-
Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population Clin. Kidney J. (IF 4.6) Pub Date : 2024-03-05 Navdeep Tangri, Thomas Ferguson, Silvia J Leon, Stefan D Anker, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Luis M Ruilope, Alfredo E Farjat, Youssef M K Farag, Patrick Schloemer, Robert Lawatscheck, Katja Rohwedder, George L Bakris
Background Chronic kidney disease (CKD) affects > 800 million individuals worldwide and is often under-recognized. Early detection, identification, and treatment can delay disease progression. Klinrisk is a proprietary risk prediction model based on common laboratory data to predict CKD progression. We aimed to externally validate the Klinrisk model for prediction of CKD progression in FIDELITY (a
-
Gut Permeability, Circulating Bacterial Fragments, and Measures of Congestion in Peritoneal Dialysis Clin. Kidney J. (IF 4.6) Pub Date : 2024-03-05 Chuanlei Li, Jack Kit-Chung Ng, Gordon Chun-Kau Chan, Winston Wing-Shing Fung, Ka-Bik Lai, Peter Yam-Kau Poon, Cathy Choi-Wan Luk, Kai-Ming Chow, Cheuk-Chun Szeto
Background Limited data exists on the association between gut permeability, circulating bacterial fragment, and volume overload in peritoneal dialysis (PD) patients. We measured circulating bacterial fragments, NT-proBNP, calprotectin, and zonulin levels, and evaluate their association with the clinical outcomes in PD patients. Methods This is a single-center prospective study on 108 consecutive incident
-
The diagnosis of acute interstitial nephritis caused by infection versus antibiotic-induced interstitial nephritis: a narrative review Clin. Kidney J. (IF 4.6) Pub Date : 2024-03-01 Amir Muhammad, Yingli Zhang, Ling Huang, Qiongjing Yuan, Wei Wang, Jiaxi Pu, Wei Lin, Rong Tang, Xiangcheng Xiao
Acute interstitial nephritis (AIN) is a significant contributor to acute kidney injury (AKI) and can be attributed to a variety of factors, including but not limited to allergens or drugs, infections, autoimmune or systemic diseases, and idiopathic forms of the disease. In some cases, AIN requires a therapeutic action according to a single specific etiology by handling the offending agent and applying
-
Associations between inflammatory and angiogenic proteomic biomarkers, and cardiovascular events and mortality in relation to kidney function Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-29 Barbara Salzinger, Kristina Lundwall, Marie Evans, Josefin Mörtberg, Håkan Wallén, Tomas Jernberg, Thomas Kahan, Pia Lundman, Per Tornvall, David Erlinge, Bertil Lindahl, Tomasz Baron, Melinda Rezeli, Jonas Spaak, Stefan H Jacobson
Background The links between chronic kidney disease (CKD) and the high burden of cardiovascular disease remain unclear. We aimed to explore the association between selected inflammatory and angiogenic biomarkers, kidney function and long-term outcome in patients with an acute coronary syndrome (ACS), and to test the hypothesis that CKD status modify this association. Methods 1293 ACS patients hospitalized
-
Growing Concerns About Using Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for the Treatment of Renal Anemia Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-29 Takeshi Nakanishi, Takahiro Kuragano
Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) have emerged as a novel therapeutic class for treating anemia in patients with chronic kidney disease. Small molecule analogs of α-ketoglutarate (AKG), an essential substrate for 2-oxoglutarate-dependent dioxygenases (2-OGDDs), including prolyl hydroxylase domain proteins (PHDs), inhibit PHD pharmacologically and thereby prevent HIF
-
Recovery from kidney failure associated with chronic thromboembolic pulmonary hypertension following pulmonary thomboendarterectomy Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-29 George M Nassar, Robert Jameson, Steffi Sathiyaraj, Nayda Bidikian, Nelson Villasmil-Hernandez, Sandeep Sahay
The occurrence of renal failure in pulmonary hypertension (PH) is an ominous sign and implies excessive adverse hemodynamic factors. Pharmacologic agents to treat the PH are the mainstay of management whereas diuretics assist in management of fluid overload. However, when such measures fail, dialysis and ultrafiltration (UF) become necessary to manage progressive azotemia and hypervolemia. Reversal
-
Differential associations of fetuin-a and calcification propensity with cardiovascular events and subsequent mortality in patients undergoing hemodialysis Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-28 Katsuhito Mori, Tetsuo Shoji, Shinya Nakatani, Hideki Uedono, Akinobu Ochi, Hisako Yoshida, Yasuo Imanishi, Tomoaki Morioka, Yoshihiro Tsujimoto, Makoto Kuro-o, Masanori Emoto
Background Fetuin-A inhibits precipitation of calcium-phosphate crystals by forming calciprotein particles (CPP). A novel T50 test, which measures transformation time from primary to secondary CPP, is an index for calcification propensity. Both lower fetuin-A and shorter T50 levels were associated with cardiovascular disease (CVD) risk in patients with chronic kidney disease (CKD). Extremely high risk
-
Performance of an interstitial glucose monitoring device freestyle libre 2 in patients with type 1 diabetes during haemodialysis Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-27 Sophie Cornet, Olivier Moranne, François Jouret, Marie Christine Parotte, Benoit Georges, Eric Godon, Etienne Cavalier, Régis P Radermecker, Pierre Delanaye
Background The use of interstitial glucose monitoring devices such as Flash Glucose Monitoring has been shown to be beneficial in patients with type 1 diabetes (T1DM). However, these devices have been little studied in patients with diabetes treated by chronic haemodialysis (HD). Methods The goal of this prospective, observational, multicentric, study was to evaluate the analytical performance of the
-
Ionized and total magnesium levels in patients with chronic kidney disease: associated factors and outcomes Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-22 Maxime Pluquet, Said Kamel, Natalia Alencar de Pinho, Nicolas Mansencal, Christian Combe, Marie Metzger, Ziad A Massy, Sophie Liabeuf, Solène M Laville
Background and hypothesis Association between hypo- and/or hypermagnesaemia and cardiovascular (CV) outcomes or mortality showed conflicting results in chronic kidney disease (CKD) and was conducted on total magnesium (tMg) levels. Thus, the objectives of the present study were to (i) describe the serum ionized Mg (iMg) concentration in patients at various CKD stages, (ii) measure the correlation between
-
Mortality and hyperkalaemia-associated hospitalisation in patients with chronic kidney disease: comparison of sodium zirconium cyclosilicate and sodium/calcium polystyrene sulfonate Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-21 Chikao Onogi, Yu Watanabe, Akihito Tanaka, Kazuhiro Furuhashi, Shoichi Maruyama
Background Sodium zirconium cyclosilicate (SZC), a novel drug used for treating hyperkalaemia, is effective in reducing serum potassium levels. The effects of potassium adsorbents on the mortality and hyperkalaemia-associated hospitalisation rates remain unclear. We aimed to examine how mortality and hyperkalaemia-associated hospitalisation rates vary with usage of various potassium adsorbents. Methods
-
Effect of urine alkalization on urinary inflammatory markers in cystinuric patients Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-21 Caroline Prot-Bertoye, Vincent Jung, Isabelle Tostivint, Kevin Roger, Jean-François Benoist, Anne-Sophie Jannot, Alexis Van Straaten, Bertrand Knebelmann, Ida Chiara Guerrera, Marie Courbebaisse
Background Cystinuria is associated to a high prevalence of chronic kidney disease (CKD). We previously described a urinary inflammatory protein signature (UIS), including 38 up-regulated proteins, in cystinuric patients (Cys-patients), compared to healthy controls (HC). This UIS was higher in Cys-patients with CKD. In the present observational study, we aimed at investigating the UIS in Cys-patients
-
Risk of incident chronic kidney disease among patients with urolithiasis: a nationwide longitudinal cohort study Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-20 Jae Young Kim, Jae Kwang Lee, Jung Tak Park, Tae Ik Chang
Background Urolithiasis has been infrequently implicated to have a causal association with chronic kidney disease (CKD). Recently, several studies have demonstrated the relationship between urolithiasis and CKD. However, the generalizability of their results is limited. This study aimed to investigate the association between urolithiasis and the risk of incident CKD. Methods This longitudinal cohort
-
Transient acute kidney injury after Chimeric Antigen Receptor T-cell therapy in patients with hematological malignancies Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-20 Juan León-Román, Gloria Iacoboni, Sheila Bermejo, Cecilia Carpio, Mónica Bolufer, Clara García-Carro, Mario Sánchez-Salinas, Carla Alonso-Martínez, Oriol Bestard, Pere Barba, María José Soler
Acute kidney injury (AKI) occurs in 30% of patients infused with chimeric antigen receptor (CAR) T-cells. The purpose of this study was to identify risk factors and long-term outcomes after AKI in patients who received CAR T-cell therapy. A total of 24/115(21%) patients developed AKI related to CAR T-cell therapy; 6/24 with AKI over chronic kidney disease (CKD). Two patients had AKI in the context
-
Making the invisible visible: imaging techniques for assessing muscle mass and muscle quality in chronic kidney disease Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-19 Alice Sabatino, Kristoffer Huitfeldt Sola, Torkel B Brismar, Bengt Lindholm, Peter Stenvinkel, Carla Maria Avesani
Muscle wasting and low muscle mass are prominent features of protein energy wasting (PEW), sarcopenia and sarcopenic obesity in patients with chronic kidney disease (CKD). In addition, muscle wasting is associated with low muscle strength, impaired muscle function, and adverse clinical outcomes such as low quality of life, hospitalizations, and increased mortality. While assessment of muscle mass is
-
Circulating miR-129-3p in combination with clinical factors predicts vascular calcification in hemodialysis patients Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-17 Jingjing Jin, Meijuan Cheng, Xueying Wu, Haixia zhang, Dongxue Zhang, Xiangnan Liang, Yuetong Qian, Liping Guo, Shenglei Zhang, Yaling Bai, Jinsheng Xu
Background Vascular calcification (VC) commonly occurs and seriously increases the risk of cardiovascular events and mortality in patients with hemodialysis. For optimizing individual management, we will develop a diagnostic multivariable prediction model for evaluating the probability of VC. Methods The study was conducted in four steps. First, identification of miRNAs regulating osteogenic differentiation
-
Monoallelic pathogenic IFT140 variants are a common cause of autosomal dominant polycystic kidney disease-spectrum phenotype Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-17 Chiara Dordoni, Letizia Zeni, Diego Toso, Cinzia Mazza, Federica Mescia, Roberta Cortinovis, Laura Econimo, Gianfranco Savoldi, Federico Alberici, Francesco Scolari, Claudia Izzi1
Background Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common inherited kidney disorder, characterized by development and enlargement of kidney cysts, eventually leading to end-stage kidney disease (ESKD). Pathogenic variants in PKD1 or PKD2 genes are the major cause of ADPKD; additional rare variants in GANAB, DNAJB11, ALG5, ALG9 genes have been found in a minority of ADPKD patients
-
Anticoagulation in patients with end-stage kidney disease and atrial fibrillation: a national population-based study Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-16 Deok-Gie Kim, Sung Hwa Kim, Sung Yong Park, Byoung Geun Han, Jae Seok Kim, Jae Won Yang, Young Jun Park, Jun Young Lee
Background The prevalence of atrial fibrillation (AF) in patients with end-stage kidney disease (ESKD) is high and increasing. However, evidence regarding oral anticoagulant (OAC) use in these patients is insufficient and conflicting. Methods This retrospective cohort study included patients in the Korea National Health Insurance System diagnosed with AF after ESKD onset from January 2007 to December
-
Characterization of glomerular basement membrane components within pediatric glomerular diseases Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-16 Dan Chen, Xindi Zhou, Chun Gan, Qing Yang, Wanbing Chen, Xiaoqian Feng, Tao Zhang, Li Zhang, Lujun Dai, Yaxi Chen, Haiping Yang, Mo Wang, Wei Jiang, Qiu Li
Background Disruptions in gene expression associated with the glomerular basement membrane (GBM) could precipitate glomerular dysfunction. Nevertheless, a comprehensive understanding of the characterization of GBM components within pediatric glomerular diseases and their potential association with glomerular function necessitates further systematic investigation. Methods We conducted a systematic analysis
-
Actioning the findings of hard end point clinical trials as they emerge in the realm of chronic kidney disease care: a review and a call to action Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-10 Giovanni F M Strippoli, Suetonia C Green
Fewer than half of patients treated with hemodialysis survive five years. Multiple therapeutics are used to address the complications of advanced chronic kidney disease but most have not been found to improve clinical outcomes. Clinical trials of treatment innovations for chronic kidney diseases and dialysis care have been suboptimal in number and quality. Recent trials are changing this trend. Practice
-
Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-10 Phil McEwan, Jason A Davis, Peter D Gabb, David C Wheeler, Peter Rossing, Glenn M Chertow, Ricardo Correa-Rotter, Kouichi Tamura, Salvatore Barone, Juan Jose Garcia Sanchez
Introduction The DAPA-CKD trial enrolled patients with estimated glomerular filtration rate 25–75 ml/min/1.73m2 and urine albumin-to-creatinine ratio >200 mg/g. The DECLARE-TIMI 58 trial enrolled patients with type 2 diabetes, a higher range of kidney function and no albuminuria criterion. The study objective was to estimate the cost-effectiveness of dapagliflozin in a broad chronic kidney disease
-
Renal function alters the association of lipoprotein(a) with cardiovascular outcomes in patients undergoing percutaneous coronary intervention: a prospective cohort study Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-10 Guyu Zeng, Pei Zhu, Deshan Yuan, Peizhi Wang, Tianyu Li, Qinxue Li, Jingjing Xu, Xiaofang Tang, Ying Song, Yan Chen, Ce Zhang, Sida Jia, Ru Liu, Lin Jiang, Lei Song, Runlin Gao, Yuejin Yang, Xueyan Zhao, Jinqing Yuan
Background and hypothesis lipoprotein(a) [Lp(a)] and renal dysfunction are both independent risk factors for cardiovascular disease. However, it remains unclear whether renal function mediates the association between Lp(a) and cardiovascular outcomes in patients undergoing percutaneous coronary intervention (PCI). Methods From a large prospective cohort study, 10 435 eligible patients undergoing PCI
-
Imlifidase in Kidney Transplantation Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-10 Mehmet Kanbay, Sidar Copur, Mustafa Guldan, Ahmet U Topcu, Lasin Ozbek, Baris Hasbal, Caner Süsal, Burak Kocak, Jasper Callemeyn, Mårten Segelmark
Kidney transplantation, the gold standard therapeutic approach for patients with end-stage kidney disease, offers improvement in patient survival and quality of life. However, broad sensitization against human leukocyte antigens often resulting in a positive crossmatch against the patient's living donor or the majority of potential deceased donors in the allocation system represents a major obstacle
-
Association between beta-blocker utilization and heart failure mortality in the peritoneal dialysis population: a cohort study Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-10 Meizhu Gao, Han Chen, Fang Cao, Li Zhang, Yiping Ruan, Weihua Liu, Fuyuan Hong, Jiewei Luo, Miao Lin
Background The prognostic significance of β-blocker therapy in patients at end-stage renal disease, specifically those receiving peritoneal dialysis (PD) and presenting with heart failure, remains inadequately elucidated due to limited research conducted thus far. Methods A retrospective analysis was performed on a cohort comprising 608 patients receiving PD between September 2007 and March 2019, with
-
Loin Pain Haematuria Syndrome 1967 – 2020: a Review Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-10 Nicholas M P Annear, Jill Vanmassenhove, Norbert Lameire, Malcolm E Phillips, John B Eastwood
The purpose of this retrospective review is to question the validity of the condition “Loin Pain Haematuria Syndrome” (LPHS). We highlight the possibility that most patients regarded as having LPHS have a psychiatric/psychological basis for their symptoms, particularly loin pain. Because of this, and because it recurs despite treatment, the review also questions the use of treatments that are invasive
-
Management of de-novo nephrolithiasis after kidney transplantation: a comprehensive review from the European Renal Association CKD-MBD working group Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-07 Mehmet Kanbay, Sidar Copur, Cicek N Bakir, Alper Hatipoglu, Smeeta Sinha, Mathias Haarhaus
The lifetime incidence of kidney stones is 6-12% in the general population. Nephrolithiasis is a known cause of acute and chronic kidney injury, mediated via obstructive uropathy or crystal-induced nephropathy, and several modifiable and non-modifiable genetic and lifestyle causes have been described. Evidence for epidemiology and management of nephrolithiasis after kidney transplantation is limited
-
Morphometric analysis of chronicity on kidney biopsy: a useful prognostic exercise Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-06 Muhammad S Asghar, Aleksandar Denic, Andrew D Rule
Chronic changes on kidney biopsy specimens include increasing amounts of arteriosclerosis, glomerulosclerosis, interstitial fibrosis and tubular atrophy, enlarged nephron size, and reduced nephron number. These chronic changes are difficult to accurately assess by visual inspection but are reasonably quantified using morphometry. This review describes the various patient populations that have undergone
-
Safety and efficacy of glucagon-like peptide-1 receptor agonists among Kidney transplant recipients: a systematic review and meta-analysis Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-03 Pajaree Krisanapan, Supawadee Suppadungsuk, Kanokporn Sanpawithayakul, Charat Thongprayoon, Pattharawin Pattharanitima, Supawit Tangpanithandee, Michael A Mao, Jing Miao, Wisit Cheungpasitporn
Background Evidence supporting glucagon-like peptide-1 receptor agonists (GLP-1RAs) in kidney transplant recipients (KTRs) remains scarce. This systematic review and meta-analysis aims to evaluate the safety and efficacy of GLP-1RAs in this population. Method A comprehensive literature search was conducted in MEDLINE, EMBASE, and Cochrane Database from inception through May 2023. Clinical trials and
-
Incremental dialysis: two complementary views Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-02 Francesco Gaetano Casino, Marianna Murea, Jürgen Floege, Carmine Zoccali
Franco Casino and Marianna Murea discuss today's knowledge about the ‘incremental dialysis’ concept. Franco Casino frames the problem by saying that, in the presence of substantial residual kidney function, kidney replacement therapy can begin with low doses and/or frequencies, to be gradually increased to compensate for any subsequent losses of residual kidney function, keeping the total clearance
-
Recognition of intraglomerular histological features with deep learning in protocol transplant biopsies and its association with kidney function and prognosis Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-01 Imane Farhat, Elise Maréchal, Doris Calmo, Manon Ansart, Michel Paindavoine, Patrick Bard, Georges Tarris, Didier Ducloux, Sophie Adrian Felix, Laurent Martin, Claire Tinel, Jean-Baptiste Gibier, Mathilde Funes de la Vega, Jean-Michel Rebibou, Jamal Bamoulid, Mathieu Legendre
Background and hypothesis The Banff classification may not adequately address protocol transplant biopsies categorized as normal in patients experiencing unexplained graft function deterioration. This study seeks to employ convolutional neural networks to automate the segmentation of glomerular cells and capillaries and assess their correlation with transplant function. Methods 215 patients were categorized
-
The risk of CKD progression remains high in patients treated with ACE and Angiotensin II antagonists, mineralocorticoid receptor antagonists and SGLT2 inhibitors. Have we already achieved the therapeutic ceiling in CKD? (CON part) Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-01 Matias Trillini, Piero Ruggenenti
Renin-Angiotensin-System (RAS) inhibitors remained the only effective nephro-protective treatments until recent land-mark trials showed that sodium-glucose co-transporter 2 (SGLT2) inhibitors and non-steroid mineral receptor antagonists added-on RAS inhibitor therapy dramatically slowed renal disease progression in patients with chronic kidney disease (CKD). However, despite this impressive advancement
-
Use of ACEi/ARBs, SGLT-2 inhibitors and MRAs can help us reach the therapeutic ceiling in CKD Clin. Kidney J. (IF 4.6) Pub Date : 2024-02-01 Pantelis Sarafidis
Chronic kidney disease (CKD) is increasing in prevalence worldwide posing major implications for public health, such as kidney failure requiring dialysis and increased risk of cardiovascular and all-cause mortality. Diabetic and hypertensive kidney disease represent the two most common causes of CKD. Until a few years ago, lifestyle modifications, blood pressure, glycemic and lipid control, along with
-
Microangiopathy associated with poor outcome of IgA nephropathy: a cohort study and meta-analysis Clin. Kidney J. (IF 4.6) Pub Date : 2024-01-25 Lei Dong, Yuncan Hu, Dan Yang, Liu Liu, Yueqiang Li, Shuwang Ge, Ying Yao
Background Microangiopathy (MA) lesions are not rare in immunoglobulin A nephropathy (IgAN) and have been suggested a potential role of increasing risk in renal function decline. However, this suggestion has not been universally accepted. We aimed to investigate its role in our cohort and in multiple studies through a systematical meta-analysis. Methods This cohort study included 450 IgAN patients
-
Potentially modifiable factors associated with health-related quality of life among people with chronic kidney disease: baseline findings from the National Unified Renal Translational Research Enterprise CKD (NURTuRE-CKD) cohort Clin. Kidney J. (IF 4.6) Pub Date : 2024-01-17 Thomas Phillips, Scott Harris, Olalekan Lee Aiyegbusi, Bethany Lucas, Melissa Benavente, Paul J Roderick, Paul Cockwell, Philip A Kalra, David C Wheeler, Maarten W Taal, Simon D S Fraser
Background and hypothesis Many non-modifiable factors are associated with poorer health-related quality of life (HRQoL) experienced by people with chronic kidney disease (CKD). We hypothesise that potentially modifiable factors for poor HRQoL can be identified among CKD patients, providing potential targets for intervention. Method The NURTuRE-CKD cohort study recruited 2996 participants from nephrology
-
Comparison of three creatinine-based equations to predict adverse outcome in a cardiovascular high-risk cohort: An investigation using the SPRINT research materials Clin. Kidney J. (IF 4.6) Pub Date : 2024-01-17 Insa E Emrich, John W Pickering, Felix Götzinger, Rafael Kramann, Michael Kunz, Lucas Lauder, Vasilios Papademetriou, Michael Böhm, Gunnar H Heine, Felix Mahfoud
Background Novel creatinine-based equations have recently been proposed but their predictive performance for cardiovascular outcomes in participants at high cardiovascular risk in comparison to the established CKD-EPI 2009 equation is unknown. Methods In 9,361 participants from the United States included in the randomized controlled SPRINT trial, we calculated baseline estimated glomerular filtration
-
Kidney Failure Risk Equation in vascular access planning: a population-based study supporting value in decision making Clin. Kidney J. (IF 4.6) Pub Date : 2024-01-12 Mohammad Atiquzzaman, Bingyue Zhu, Alexandra Romann, Lee Er, Ognjenka Djurdjev, Micheli Bevilacqua, Michelle Wong, Peter Birks, Tae Won Yi, Anurag Singh, Navdeep Tangri, Adeera Levin
Background and hypothesis Kidney Failure Risk Equation(KFRE) can play a better role in vascular access(VA) planning in patients with CKD requiring hemodialysis(HD). We described the eGFR referral-based VA creation and utilization pattern and investigated the utility of KFRE score as an adjunct variable in VA planning. Methods Patients with CKD aged ≥18 years with eGFR <20ml/min/1.73m2 who chose HD
-
An increase in albuminuria is associated with a higher incidence of malignancies Clin. Kidney J. (IF 4.6) Pub Date : 2024-01-11 Li Luo, Lyanne M Kieneker, Yuanhang Yang, Roemer J Janse, Alessandro Bosi, Rudolf A de Boer, Priya Vart, Juan-Jesus Carrero, Ron T Gansevoort
Background A single albuminuria measurement is reported to be an independent predictor of cancer risk. Whether change in albuminuria is also independently associated with cancer is not known. Methods We included 64,303 subjects of the Stockholm Creatinine Measurements (SCREAM) project without a history of cancer and with at least 2 urine albumin-creatinine ratio (ACR) tests up to 2 years apart. Albuminuria
-
Comparison of different estimated glomerular filtration rates for monitoring of kidney function in oncology patients Clin. Kidney J. (IF 4.6) Pub Date : 2024-01-11 Tijl Vermassen, Karen Geboes, Nicolaas Lumen, Charles Van Praet, Sylvie Rottey, Joris Delanghe
Background Tyrosine kinase inhibitors (TKIs) are associated with kidney function deterioration. A shift is ongoing towards glomerular filtration rate (GFR) equations based on other protein markers, such as cystatin C (CSTC) and β-trace protein (BTP). We evaluated various GFR equations for monitoring of kidney function in actively treated oncology patients. Methods We monitored 110 patients receiving
-
Pruritus and protein-bound uremic toxins in patients undergoing hemodialysis: a cross-sectional study Clin. Kidney J. (IF 4.6) Pub Date : 2024-01-10 Suguru Yamamoto, Takahiro Tanaka, Kentaro Omori, Isei Ei, Kaori Kikuchi, Ayano Konagai, Shin Goto, Nobutaka Kitamura, Ichiei Narita
Background Patients undergoing hemodialysis frequently experience pruritus; its severity is associated with poor quality of life and mortality. Recent progress in hemodialysis treatment has improved the removal of small- and middle-molecular-weight molecules; however, the removal of protein-bound uremic toxins (PBUTs) remains difficult. It is possible that pruritus is associated with serum PBUTs in
-
The spectrum of thrombotic microangiopathy related to monoclonal gammopathy Clin. Kidney J. (IF 4.6) Pub Date : 2024-01-09 Daan P C van Doorn, Myrurgia A Abdul-Hamid, Leon A M Frenken, Pieter van Paassen, Sjoerd A M E G Timmermans
Background Recent studies showed a high prevalence of monoclonal gammopathy (MG) in patients with thrombotic microangiopathy (TMA) aged over 50 years and suggested that complement dysregulation is pivotal for the disease to develop. Here, we studied this premise in 7 patients with TMA and coexisting MG. Methods Patients with TMA on kidney biopsy and/or peripheral blood were recruited from the prospective
-
Sex disparities in the utilization of nurse-assisted peritoneal dialysis: a mediation analysis using data from the REIN registry Clin. Kidney J. (IF 4.6) Pub Date : 2024-01-04 Isabelle Danneville, Mathilde Beaumier, Annabel Boyer, Valérie Chatelet, Elisabeth Monnet, Stéphane Edet, Antoine Lanot, Clémence Bechade, Thierry Lobbedez
Background This study was carried out to evaluate the association between patient sex and the proportion of nurse-assisted peritoneal dialysis (PD) at dialysis initiation and to explore whether sex disparities in nurse-assisted PD utilization was explained by predialysis care and/or by social deprivation using mediation analysis. Methods This was a retrospective study using data from the Renal Epidemiology
-
Elimination and penetration of Amikacin into urine in patients with decreased glomerular filtration rate Clin. Kidney J. (IF 4.6) Pub Date : 2024-01-04 Jan Miroslav Hartinger, Eliška Dvořáčková, Vojtěch Krátký, Zdenka Hrušková, Marek Mysliveček, Daniel Bobek, Hana Benáková, Jan Závora, Gabriela Kroneislová, Barbora Agatha Halouzková, Martina Brejníková, Vendula Martínková, Vladimír Tesař, Ondřej Slanař
Background Amikacin monotherapy is recommended for UTI treatment with multi-resistant pathogens. Even though amikacin efficacy in the treatment of UTIs is dependent on its urinary concentration, there are no robust data proving that sufficiently high urinary concentration is reached in patients with reduced glomerular filtration rate. Methods Prospective study to monitor amikacin penetration into urine
-
Ambient temperature and the occurrence of intradialytic hypotension in patients receiving hemodialysis Clin. Kidney J. (IF 4.6) Pub Date : 2023-12-22 Kuan-Hung Liu, Wei-Hsiang Chang, Edward Chia-Cheng Lai, Pei-Chen Tsai, Bin Hsu, Yu-Hsuan Yang, Wei-Ren Lin, Tzu-Shan Huang, Fang-Yi Su, Jung-Hsien Chiang, Chung-Yi Li, Yau-Sheng Tsai, Junne-Ming Sung
Background Intradialytic hypotension (IDH) is a common hemodialysis complication causing adverse outcomes. Despite the well-documented associations of ambient temperatures with fluid removal and pre-dialysis blood pressure, the relationship between ambient temperature and IDH has not been adequately studied. Methods We conducted a cohort study at a tertiary hospital in southern Taiwan between January
-
Gut-immune axis and cardiovascular risk in chronic kidney disease Clin. Kidney J. (IF 4.6) Pub Date : 2023-12-14 Felix Behrens, Hendrik Bartolomaeus, Nicola Wilck, Johannes Holle
Patients with chronic kidney disease (CKD) suffer from marked cardiovascular morbidity and mortality, so lowering the cardiovascular risk is paramount to improve quality of life and survival in CKD. Manifold mechanisms are hold accountable for the development of cardiovascular disease (CVD), and recently inflammation arose as novel risk factor significantly contributing to progression of CVD. While
-
Novel biomarkers and pathophysiology of membranous nephropathy: PLA2R and beyond Clin. Kidney J. (IF 4.6) Pub Date : 2023-12-12 Corrado Murtas, Maurizio Bruschi, Sonia Spinelli, Xhuliana Kajana, Enrico E Verrina, Andrea Angeletti, Gianluca Caridi, Giovanni Candiano, Sandro Feriozzi, Marco Prunotto, Gian Marco Ghiggeri
Research on membranous nephropathy truly exploded in the last 15 years. This happened because of the application of new techniques (laser capture microdissection, mass spectrometry, protein G immunoprecipitation, arrays) to the study of its pathogenesis. After the discovery of PLA2R as the major target antigen, many other antigens were identified and others are probably ongoing. Clinical and pathophysiology
-
Cost-effectiveness of screening for chronic kidney disease: existing evidence and knowledge gaps Clin. Kidney J. (IF 4.6) Pub Date : 2023-12-10 Dominique van Mil, Xavier G L V Pouwels, Hiddo J L Heerspink, Ron T Gansevoort
It is well known that the worldwide prevalence of chronic kidney disease (CKD) has risen to over 10% of the general population during the last decades. Patients with CKD are at increased risk of both kidney failure and cardiovascular disease (CVD), posing a substantial health challenge. Therefore, screening for CKD is warranted to identify and treat patients early to prevent progression and complications
-
Nephrology Partnership for Advancing Technology in Healthcare (N-PATH) program: the teachers’ perspective Clin. Kidney J. (IF 4.6) Pub Date : 2023-12-09 Carlo Lomonte, Michele Rossini, Josè Ibeas, Mauro Forcella, Jadranka Buturovic Ponikvar, Maurizio Gallieni, Roberto Russo, Dimitris Goumenos, Vladimir Tesar, Zdenka Hruskova, Joris Roelofs, Sandrine Florquin, Maarten Snoeijs, Antonio Giusto, David Shemesh, Joris Rotmans, Roser Torra, Christoph Wanner, Loreto Gesualdo
The N-PATH (Nephrology Partnership for Advancing Technology in Healthcare) program concluded with the 60th European Renal Association 2023 congress in Milan, Italy. This collaborative initiative aimed to provide advanced training in interventional nephrology to young European nephrologists. Funded by Erasmus + Knowledge Alliance, N-PATH addressed the global burden of chronic kidney disease (CKD) and
-
Comparison of Outcomes on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHIs) in Anaemia Associated with Chronic Kidney Disease: Network Meta-Analyses in Dialysis and Non-Dialysis Dependent Populations Clin. Kidney J. (IF 4.6) Pub Date : 2023-12-07 Alfred Sackeyfio, Renato D Lopes, Csaba P Kovesdy, Aleix Cases, Steve A Mallett, Nick Ballew, Tom J Keeley, Viviana Garcia-Horton, Rajeev Ayyagari, Rodrigo Refoios Camejo, Kirsten L Johansen, Alexander J Sutton, Indranil Dasgupta
Background Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are oral alternatives to current standard-of-care treatments for anaemia in chronic kidney disease (CKD). We conducted network meta-analyses to indirectly compare clinical outcomes for three HIF-PHIs in dialysis and non-dialysis populations with anaemia in CKD. Methods The evidence base comprised phase III, randomised, controlled
-
Differentiating primary and secondary FSGS using non-invasive urine biomarkers Clin. Kidney J. (IF 4.6) Pub Date : 2023-12-05 Lorenzo Catanese, Justyna Siwy, Ralph Wendt, Kerstin Amann, Joachim Beige, Bruce Hendry, Harald Mischak, William Mullen, Ian Paterson, Mario Schiffer, Michael Wolf, Harald Rupprecht
Background Focal segmental glomerulosclerosis (FSGS) is divided into genetic, primary (p), uncertain cause, and secondary (s) forms. The subclasses differ in management and prognosis with differentiation often being challenging. We aimed to identify specific urine proteins/peptides discriminating between biopsy-proven pFSGS and sFSGS. Methods 63 urine samples were collected in two different centers
-
Real-world usage of Chronic Kidney Disease - mineral bone disorder (CKD-MBD) biomarkers in nephrology practices Clin. Kidney J. (IF 4.6) Pub Date : 2023-11-30 Maria Fusaro, Simona Barbuto, Maurizio Gallieni, Althea Cossettini, Giulia Vanessa Re Sartò, Laura Cosmai, Giuseppe Cianciolo, Gaetano La Manna, Thomas Nickolas, Serge Ferrari, Jordi Bover, Mathias Haarhaus, Carmela Marino, Maria Cristina Mereu, Maura Ravera, Mario Plebani, Martina Zaninotto, Mario Cozzolino, Stefano Bianchi, Piergiorgio Messa, Mariacristina Gregorini, Lorenzo Gasperoni, Caterina Agosto
Background Chronic kidney disease mineral bone disorder (CKD-MBD) is a condition characterized by alterations of calcium, phosphate, parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF-23) metabolism that in turn promote bone disorders, vascular calcifications and increase cardiovascular (CV) risk. Nephrologists' awareness of diagnostic, prognostic, and therapeutic tools to manage CKD-MBD
-
Risk factors for Covid-19 hospitalization and mortality in patients with chronic kidney disease: a nationwide cohort study Clin. Kidney J. (IF 4.6) Pub Date : 2023-11-29 Angelica Artborg, Aurora Caldinelli, Julia Wijkström, Alexandra Nowak, Michael Fored, Maria Stendahl, Marie Evans, Helena Rydell
Background Several studies have demonstrated an increased risk of severe Covid-19 in chronic kidney disease (CKD) patients. However, few have investigated the impact of CKD stage and dialysis modality. The primary aim of this study was to investigate the association between CKD stage, dialysis modality and risk of severe Covid-19. Secondly, we aimed to study the impact of comorbidities and drugs on
-
All-cause and immune checkpoint inhibitor-associated acute kidney injury in immune checkpoint inhibitors users: a meta-analysis of occurrence rate, risk factors, and mortality Clin. Kidney J. (IF 4.6) Pub Date : 2023-11-29 Jia-Jin Chen, Tao-Han Lee, George Kuo, Chieh-Li Yen, Cheng-Chia Lee, Chih-Hsiang Chang, Kun-Hua Tu, Yung-Chang Chen, Ji-Tseng Fang, Cheng-Chieh Hung, Chih-Wei Yang, Wen-Chi Chou, Ching-Chi Chi, Yu-Kang Tu, Huang-Yu Yang
Background It is noted immune checkpoint inhibitors (ICIs) were associated with AKI. However, the occurrence rate of ICIs-related AKI was not been systematically examined. Additionally, exposure to PPI and NSAID were considered as a risk factor for AKI but with inconclusive results in ICIs related AKI. Our aim was to analyze the occurrence rate of all-cause AKI and ICIs-related AKI, to analyze the